BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Shen WF, Zhong W, Liu Q, Sui CJ, Huang YQ, Yang JM. Adjuvant transcatheter arterial chemoembolization for intrahepatic cholangiocarcinoma after curative surgery: retrospective control study. World J Surg. 2011;35:2083-2091. [PMID: 21698503 DOI: 10.1007/s00268-011-1171-y] [Cited by in Crossref: 41] [Cited by in F6Publishing: 42] [Article Influence: 4.1] [Reference Citation Analysis]
Number Citing Articles
1 Yamamoto Y, Sugiura T, Todaka A, Okamura Y, Ito T, Ashida R, Kakuda Y, Nakanuma Y, Uesaka K. Surgical Indication for Advanced Intrahepatic Cholangiocarcinoma According to the Optimal Preoperative Carbohydrate Antigen 19-9 Cutoff Value. World J Surg 2018;42:3331-40. [DOI: 10.1007/s00268-018-4605-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
2 Kis B, El-Haddad G, Sheth RA, Parikh NS, Ganguli S, Shyn PB, Choi J, Brown KT. Liver-Directed Therapies for Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. Cancer Control 2017;24:1073274817729244. [PMID: 28975829 DOI: 10.1177/1073274817729244] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
3 Weber SM, Ribero D, O'Reilly EM, Kokudo N, Miyazaki M, Pawlik TM. Intrahepatic cholangiocarcinoma: expert consensus statement. HPB (Oxford). 2015;17:669-680. [PMID: 26172134 DOI: 10.1111/hpb.12441] [Cited by in Crossref: 177] [Cited by in F6Publishing: 212] [Article Influence: 35.4] [Reference Citation Analysis]
4 Razumilava N, Gores GJ. Cholangiocarcinoma. Lancet. 2014;383:2168-2179. [PMID: 24581682 DOI: 10.1016/s0140-6736(13)61903-0] [Cited by in Crossref: 783] [Cited by in F6Publishing: 476] [Article Influence: 111.9] [Reference Citation Analysis]
5 Halappa VG, Bonekamp S, Corona-Villalobos CP, Li Z, Mensa M, Reyes D, Eng J, Bhagat N, Pawlik TM, Geschwind JF. Intrahepatic cholangiocarcinoma treated with local-regional therapy: quantitative volumetric apparent diffusion coefficient maps for assessment of tumor response. Radiology. 2012;264:285-294. [PMID: 22627601 DOI: 10.1148/radiol.12112142] [Cited by in Crossref: 47] [Cited by in F6Publishing: 42] [Article Influence: 5.2] [Reference Citation Analysis]
6 Zhao Q, Qian S, Zhu L, Qu XD, Zhang W, Yan ZP, Cheng JM, Liu QX, Liu R, Wang JH. Transcatheter arterial chemoembolization with gemcitabine and oxaliplatin for the treatment of advanced biliary tract cancer. Onco Targets Ther 2015;8:595-600. [PMID: 25792843 DOI: 10.2147/OTT.S79316] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
7 Mosconi C, Cappelli A, Ascanio S, Pettinari I, Modestino F, Renzulli M, Galaverni MC, Cucchetti A, Gramenzi A, Pettinato C, Golfieri R. Yttrium-90 microsphere radioembolization in unresectable intrahepatic cholangiocarcinoma. Future Oncology 2017;13:1301-10. [DOI: 10.2217/fon-2017-0022] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
8 Bridgewater J, Galle PR, Khan SA, Llovet JM, Park JW, Patel T, Pawlik TM, Gores GJ. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol. 2014;60:1268-1289. [PMID: 24681130 DOI: 10.1016/j.jhep.2014.01.021] [Cited by in Crossref: 618] [Cited by in F6Publishing: 642] [Article Influence: 88.3] [Reference Citation Analysis]
9 Tarantino L, Busto G, Nasto A, Nasto RA, Tarantino P, Fristachi R, Cacace L, Bortone S. Electrochemotherapy of cholangiocellular carcinoma at hepatic hilum: A feasibility study. Eur J Surg Oncol. 2018;44:1603-1609. [PMID: 30017329 DOI: 10.1016/j.ejso.2018.06.025] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
10 Cidon EU. Resectable Cholangiocarcinoma: Reviewing the Role of Adjuvant Strategies. Clin Med Insights Oncol 2016;10:43-8. [PMID: 27199577 DOI: 10.4137/CMO.S32821] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 3.4] [Reference Citation Analysis]
11 Cheng Z, Lei Z, Jin X, Zhang Q, Si A, Yang P, Zhou J, Hartmann D, Hüser N, Shen F. Postoperative adjuvant transarterial chemoembolization for intrahepatic cholangiocarcinoma patients with microvascular invasion: a propensity score analysis. J Gastrointest Oncol 2021;12:819-30. [PMID: 34012669 DOI: 10.21037/jgo-20-443] [Reference Citation Analysis]
12 Lu Z, Liu S, Yi Y, Ni X, Wang J, Huang J, Fu Y, Cao Y, Zhou J, Fan J, Qiu S. Serum gamma-glutamyl transferase levels affect the prognosis of patients with intrahepatic cholangiocarcinoma who receive postoperative adjuvant transcatheter arterial chemoembolization: A propensity score matching study. International Journal of Surgery 2017;37:24-8. [DOI: 10.1016/j.ijsu.2016.10.015] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
13 Akateh C, Ejaz AM, Pawlik TM, Cloyd JM. Neoadjuvant treatment strategies for intrahepatic cholangiocarcinoma. World J Hepatol 2020; 12(10): 693-708 [PMID: 33200010 DOI: 10.4254/wjh.v12.i10.693] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 11.0] [Reference Citation Analysis]
14 Murakami S, Ajiki T, Okazaki T, Ueno K, Kido M, Matsumoto I, Fukumoto T, Ku Y. Factors affecting survival after resection of intrahepatic cholangiocarcinoma. Surg Today 2014;44:1847-54. [PMID: 24452507 DOI: 10.1007/s00595-013-0825-9] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 3.4] [Reference Citation Analysis]
15 Kuhlmann JB, Blum HE. Locoregional therapy for cholangiocarcinoma. Curr Opin Gastroenterol. 2013;29:324-328. [PMID: 23337933 DOI: 10.1097/mog.0b013e32835d9dea] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 2.9] [Reference Citation Analysis]
16 Li J, Wang Q, Lei Z, Wu D, Si A, Wang K, Wan X, Wang Y, Yan Z, Xia Y, Lau WY, Wu M, Shen F. Adjuvant Transarterial Chemoembolization Following Liver Resection for Intrahepatic Cholangiocarcinoma Based on Survival Risk Stratification. Oncologist. 2015;20:640-647. [PMID: 25956404 DOI: 10.1634/theoncologist.2014-0470] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 3.3] [Reference Citation Analysis]
17 Jeong S, Zheng B, Wang J, Chi J, Tong Y, Xia L, Xu N, Zhang J, Kong X, Gu J, Xia Q. Transarterial Chemoembolization: A Favorable Postoperative Management to Improve Prognosis of Hepatitis B Virus-associated Intrahepatic Cholangiocarcinoma after Surgical Resection. Int J Biol Sci. 2017;13:1234-1241. [PMID: 29104490 DOI: 10.7150/ijbs.21149] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
18 Chen YL, Jeng YM, Hsu HC, Lai HS, Lee PH, Lai PL, Yuan RH. Expression of insulin-like growth factor II mRNA-binding protein 3 predicts early recurrence and poor prognosis in intrahepatic cholangiocarcinoma. Int J Surg. 2013;11:85-91. [PMID: 23246869 DOI: 10.1016/j.ijsu.2012.11.021] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
19 Entezari P, Riaz A. Intrahepatic Cholangiocarcinoma.Semin Intervent Radiol. 2020;37:475-483. [PMID: 33328703 DOI: 10.1055/s-0040-1719188] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
20 Simo KA, Halpin LE, Mcbrier NM, Hessey JA, Baker E, Ross S, Swan RZ, Iannitti DA, Martinie JB. Multimodality treatment of intrahepatic cholangiocarcinoma: A review: Multimodality Therapy of iCCA. J Surg Oncol 2016;113:62-83. [DOI: 10.1002/jso.24093] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 5.6] [Reference Citation Analysis]
21 Yamamoto Y, Sugiura T, Okamura Y, Ito T, Ashida R, Ohgi K, Nakanuma Y, Uesaka K. The Evaluation of the Eighth Edition of the AJCC/UICC Staging System for Intrahepatic Cholangiocarcinoma: a Proposal of a Modified New Staging System. J Gastrointest Surg 2020;24:786-95. [PMID: 31012045 DOI: 10.1007/s11605-019-04185-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
22 Liu JB, Chu KJ, Ling CC, Wu TM, Wang HM, Shi Y, Li ZZ, Wang JH, Wu ZJ, Jiang XQ, Wang GR, Ma YS, Fu D. Prognosis for intrahepatic cholangiocarcinoma patients treated with postoperative adjuvant transcatheter hepatic artery chemoembolization. Curr Probl Cancer 2020;44:100612. [PMID: 32517878 DOI: 10.1016/j.currproblcancer.2020.100612] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
23 El-Diwany R, Pawlik TM, Ejaz A. Intrahepatic Cholangiocarcinoma. Surg Oncol Clin N Am. 2019;28:587-599. [PMID: 31472907 DOI: 10.1016/j.soc.2019.06.002] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 14.0] [Reference Citation Analysis]
24 Wang L, Deng M, Ke Q, Lou J, Zheng S, Bi X, Wang J, Guo W, Li F, Wang J, Zheng Y, Li J, Cheng S, Zhou W, Zeng Y. Postoperative adjuvant therapy following radical resection for intrahepatic cholangiocarcinoma: A multicenter retrospective study. Cancer Med 2020;9:2674-85. [PMID: 32072774 DOI: 10.1002/cam4.2925] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
25 Zhang SJ, Hu P, Wang N, Shen Q, Sun AX, Kuang M, Qian GJ. Thermal ablation versus repeated hepatic resection for recurrent intrahepatic cholangiocarcinoma. Ann Surg Oncol 2013;20:3596-602. [PMID: 23715967 DOI: 10.1245/s10434-013-3035-1] [Cited by in Crossref: 45] [Cited by in F6Publishing: 46] [Article Influence: 5.6] [Reference Citation Analysis]
26 Squires MH, Cloyd JM, Dillhoff M, Schmidt C, Pawlik TM. Challenges of surgical management of intrahepatic cholangiocarcinoma. Expert Rev Gastroenterol Hepatol. 2018;12:671-681. [PMID: 29911912 DOI: 10.1080/17474124.2018.1489229] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 6.3] [Reference Citation Analysis]
27 Ke Q, Lin N, Deng M, Wang L, Zeng Y, Liu J. The effect of adjuvant therapy for patients with intrahepatic cholangiocarcinoma after surgical resection: A systematic review and meta-analysis. PLoS One. 2020;15:e0229292. [PMID: 32084210 DOI: 10.1371/journal.pone.0229292] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
28 Ma KW, Cheung TT, Leung B, She BWH, Chok KSH, Chan ACY, Dai WC, Lo CM. Adjuvant chemotherapy improves oncological outcomes of resectable intrahepatic cholangiocarcinoma: A meta-analysis. Medicine (Baltimore). 2019;98:e14013. [PMID: 30702559 DOI: 10.1097/md.0000000000014013] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
29 Wu ZF, Zhang HB, Yang N, Zhao WC, Fu Y, Yang GS. Postoperative adjuvant transcatheter arterial chemoembolisation improves survival of intrahepatic cholangiocarcinoma patients with poor prognostic factors: results of a large monocentric series. Eur J Surg Oncol. 2012;38:602-610. [PMID: 22417704 DOI: 10.1016/j.ejso.2012.02.185] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
30 Wang L, Lin ZG, Ke Q, Lou JY, Zheng SG, Bi XY, Wang JM, Guo W, Li FY, Wang J, Zheng YM, Li JD, Cheng S, Zhou WP, Zeng YY. Adjuvant transarterial chemoembolization following radical resection for intrahepatic cholangiocarcinoma: A multi-center retrospective study. J Cancer 2020;11:4115-22. [PMID: 32368294 DOI: 10.7150/jca.40358] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Zhao L, Ma X, Liang M, Li D, Ma P, Wang S, Wu Z, Zhao X. Prediction for early recurrence of intrahepatic mass-forming cholangiocarcinoma: quantitative magnetic resonance imaging combined with prognostic immunohistochemical markers. Cancer Imaging 2019;19:49. [PMID: 31307551 DOI: 10.1186/s40644-019-0234-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
32 Chapiro J, Tacher V, Geschwind JF. Intraarterial therapies for primary liver cancer: state of the art. Expert Rev Anticancer Ther 2013;13:1157-67. [PMID: 24099626 DOI: 10.1586/14737140.2013.845528] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
33 Brown KM, Parmar AD, Geller DA. Intrahepatic cholangiocarcinoma. Surg Oncol Clin N Am. 2014;23:231-246. [PMID: 24560108 DOI: 10.1016/j.soc.2013.10.004] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 5.3] [Reference Citation Analysis]
34 Souche R, Addeo P, Oussoultzoglou E, Herrero A, Rosso E, Navarro F, Fabre JM, Bachellier P. First and repeat liver resection for primary and recurrent intrahepatic cholangiocarcinoma. The American Journal of Surgery 2016;212:221-9. [DOI: 10.1016/j.amjsurg.2015.07.016] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 4.6] [Reference Citation Analysis]
35 Do Minh D, Chapiro J, Gorodetski B, Huang Q, Liu C, Smolka S, Savic LJ, Wainstejn D, Lin M, Schlachter T, Gebauer B, Geschwind JF. Intra-arterial therapy of neuroendocrine tumour liver metastases: comparing conventional TACE, drug-eluting beads TACE and yttrium-90 radioembolisation as treatment options using a propensity score analysis model. Eur Radiol. 2017;27:4995-5005. [PMID: 28677067 DOI: 10.1007/s00330-017-4856-2] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 6.3] [Reference Citation Analysis]
36 Talenfeld AD, Sista AK, Madoff DC. Transarterial therapies for primary liver tumors. Surg Oncol Clin N Am. 2014;23:323-351. [PMID: 24560113 DOI: 10.1016/j.soc.2013.11.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
37 Liang W, Xu L, Yang P, Zhang L, Wan D, Huang Q, Niu T, Chen F. Novel Nomogram for Preoperative Prediction of Early Recurrence in Intrahepatic Cholangiocarcinoma. Front Oncol 2018;8:360. [PMID: 30234019 DOI: 10.3389/fonc.2018.00360] [Cited by in Crossref: 38] [Cited by in F6Publishing: 29] [Article Influence: 12.7] [Reference Citation Analysis]
38 Wu T, Jiang X, Zhang X, Wu B, Xu B, Liu X, Zheng L, Wang Y. Intrahepatic Cholangiocarcinoma: State of the Art of FGFR Inhibitors. Cancer Control 2021;28:1073274821989314. [PMID: 33618536 DOI: 10.1177/1073274821989314] [Reference Citation Analysis]
39 Cholangiocarcinoma Working Group. Italian Clinical Practice Guidelines on Cholangiocarcinoma - Part II: Treatment. Dig Liver Dis 2020;52:1430-42. [PMID: 32952071 DOI: 10.1016/j.dld.2020.08.030] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
40 Yamashita YI, Shirabe K, Beppu T, Eguchi S, Nanashima A, Ohta M, Ueno S, Kondo K, Kitahara K, Shiraishi M, Takami Y, Noritomi T, Okamoto K, Ogura Y, Baba H, Fujioka H. Surgical management of recurrent intrahepatic cholangiocarcinoma: predictors, adjuvant chemotherapy, and surgical therapy for recurrence: A multi-institutional study by the Kyushu Study Group of Liver Surgery. Ann Gastroenterol Surg 2017;1:136-42. [PMID: 29863136 DOI: 10.1002/ags3.12018] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
41 Marubashi S, Gotoh K, Takahashi H, Ohigashi H, Yano M, Ishikawa O, Sakon M. Prediction of the postoperative prognosis of intrahepatic cholangiocarcinoma (ICC): importance of preoperatively- determined anatomic invasion level and number of tumors. Dig Dis Sci 2014;59:201-13. [PMID: 24122559 DOI: 10.1007/s10620-013-2894-4] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 4.6] [Reference Citation Analysis]
42 Savic LJ, Chapiro J, Geschwind JH. Intra-arterial embolotherapy for intrahepatic cholangiocarcinoma: update and future prospects. Hepatobiliary Surg Nutr 2017;6:7-21. [PMID: 28261591 DOI: 10.21037/hbsn.2016.11.02] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]